Examples of 'carfilzomib' in a sentence
Meaning of "carfilzomib"
Carfilzomib (noun) - a drug used in the treatment of multiple myeloma. It belongs to a class of medications known as proteasome inhibitors and is sometimes prescribed in combination with other drugs for cancer therapy
Show more definitions
- A drug, that inhibits ubiquitination, used for the treatment of multiple myeloma
How to use "carfilzomib" in a sentence
Basic
Advanced
carfilzomib
Kyprolis contains the active substance carfilzomib.
Carfilzomib works by blocking the proteasome.
Similar proteasome inhibition by carfilzomib was achieved with.
Carfilzomib was rapidly and extensively metabolised.
Fertility studies with carfilzomib have not been conducted.
Cardiac disorders are known adverse drug reactions of carfilzomib.
It is unknown whether carfilzomib or its metabolites are excreted in human milk.
There is no known specific antidote for carfilzomib overdose.
Carfilzomib has the following chemical structure and name.
There are no data from the use of carfilzomib in pregnant women.
Kyprolis is a medicine that contains the active substance carfilzomib.
The pharmacokinetics of carfilzomib was studied in two dedicated renal impairment studies.
The active substance is carfilzomib.
Carfilzomib is a cytotoxic agent.
All patients should be screened for HBV before initiation of treatment with carfilzomib.
See also
Carfilzomib had antiproliferative and proapoptotic activities in preclinical models in haematologic tumours.
Process for purification of Carfilzomib.
Carfilzomib was clastogenic in the in vitro chromosomal aberration test in peripheral blood lymphocytes.
A number of cases of Hepatitis B reactivation have been identified in relation to carfilzomib treatment.
Carfilzomib is eliminated primarily via metabolism with subsequent excretion of its metabolites in urine.
In some embodiments, the proteasome inhibitor is carfilzomib.
The Carfilzomib thus obtained therein was purified by column chromatography.
In some of the foregoing embodiments, the subject is resistant bortezomib or carfilzomib.
In these aspects, carfilzomib is at a disadvantage.
In particular embodiments, the compound of formula A is administered in combination with bortezomib or carfilzomib.
In vitro, carfilzomib was found to have minimal neurotoxicity and minimal reaction to non-proteasomal proteases.
If PML is confirmed, carfilzomib must be discontinued.
PML is known safety issue of bortezomib, which belongs to the same class as carfilzomib.
Reacting said Carfilzomib oxalate with a base in a second solvent, to obtain the Carfilzomib.
Cases of Hepatitis B Virus ( HBV ) reactivation have been reported in patients receiving carfilzomib.
In vitro studies indicated that carfilzomib did not induce human CYP3A4 in cultured human hepatocytes.
Kyprolis 10 mg powder for solution for infusion carfilzomib.
There is biological plausibility for carfilzomib induced PML ( lymphopenia and opportunistic infections are expected ADRs ).
After reconstitution, 1 mL of solution contains 2 mg of carfilzomib.
Crude Carfilzomib contains undesired impurities including acetamide impurity of formula ( II ).
A process for purification of Carfilzomib of Formula I, comprising the steps of,.
Carfilzomib is the first irreversible, highly-selective, proteasome inhibitor for multiple myeloma.
Thus a method for purification of Carfilzomib of Formula I is developed as depicted in reaction Scheme 3.
Cytochrome P450 mediated mechanisms played a minor role in overall carfilzomib metabolism.
Three drugs will be tested, carfilzomib ( proteasome inhibitor ), lenalidomide ( immunomodulatory drug ) and dexamethasone synthetic glucocorticoid.
Each vial contains 10 mg of carfilzomib.
Caution should be observed when carfilzomib is combined with substrates of P-gp e.g. digoxin, colchicine.
The method of any one of claims 1 to 5, further comprising ( d ) isolating the carfilzomib vía filtration.
Oxalate salt of Carfilzomib having a structure of Formula ( III ).
Kyprolis 10 mg powder for solution for infusion Each vial contains 10 mg of carfilzomib.
The reconstituted solution contains carfilzomib at a concentration of 2 mg / mL.
Carfilzomib ( Kyprolis ) was approved by the FDA for relapsed and refractory multiple myeloma in 2012.
Clinical trials for carfilzomib continue under Onyx Pharmaceuticals, which acquired Proteolix in 2009.
Carfilzomib is a P-glycoprotein ( P-gp ) but not a BCRP substrate.
